Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers

PURPOSE: KRAS-activating mutations are the most common oncogenic driver in non-small cell lung cancer (NSCLC), but efforts to directly target mutant KRAS have proved a formidable challenge. Therefore, multi-targeted therapy may offer a plausible strategy to effectively treat KRAS-driven NSCLCs. Here...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Hai, Josephine, Liu, Shengwu, Bufe, Lauren, Do, Khanh, Chen, Ting, Wang, Xiaoen, Ng, Christine, Li, Shuai, Tsao, Ming-Sound, Shapiro, Geoffrey I., Wong, Kwok-Kin
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690829/
https://ncbi.nlm.nih.gov/pubmed/28821559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1098
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge